Should immunotherapy be the standard of care for patients with glioblastoma? – Healio
|
Should immunotherapy be the standard of care for patients with glioblastoma?
Healio Glioblastoma continues to be one of the most aggressive malignancies, with no profound breakthroughs despite incremental improvements. Patients and physicians are desperate for new treatments, and immunotherapy rapidly should become a standard of … |
